2,861
Views
6
CrossRef citations to date
0
Altmetric
Real World Evidence

Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

ORCID Icon, , , , , , & show all
Pages 114-122 | Received 28 Aug 2020, Accepted 14 Dec 2020, Published online: 18 Jan 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.